Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects

Authors: Stabin M.G.; Brill A.B.

Source: Current Pharmaceutical Biotechnology, Volume 2, Number 4, December 2001 , pp. 351-356(6)

Publisher: Bentham Science Publishers

Abstract:

A number of therapeutic agents in nuclear medicine are currently attracting considerable interest, including several for the treatment of hematologic and nonhematologic malignancies. A knowledge of the radiation dose received by different organs in the body is essential to the optimization of the therapy for each patient one wants to maximize the dose to the malignant tissue while minimizing the dose to critical healthy tissues and avoiding any toxic response therein. In this paper, current methods for calculating radiation doses will be discussed and evaluated. In almost all nuclear medicine therapy, and particularly in this application, dose to the active marrow is of paramount concern. Specific focus on current bone marrow dose models and their ability to predict observed marrow toxicity in patient populations to date will be discussed. The paper will focus on current and possible future dosimetry practice in therapeutic nuclear medicine, particularly as regards the treatment of hematologic malignancies.

Keywords: Monoclonal Antibodies; Radiation Dosimetry Aspects; Hematologic Malignancies; Carcino embryonic antigen; Radioimmunotherapy; Fluorothymidine

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201013378572

Publication date: 2001-12-01

• Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

• In this: publication
• By this: publisher
• In this Subject: Nutrition & Food ,  Biotechnology ,  Pharmacology
• By this author: Stabin M.G. ;  Brill A.B.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers